Benitec Biopharma Inc 2026年季度报告

BENITEC BIOPHARMA INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller BENITEC BIOPHARMA INC.INDEX TO FORM 10-Q SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS ITEM 1.Financial Statements5Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and June 30, 20255Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended March 31,2026 and 2025 (Unaudited)6Consolidated Statements of Stockholders’ Equity for the Three and Nine Months Ended March 31, 2026 and 2025(Unaudited)7Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2026 and 2025 (Unaudited)8Notes to Consolidated Financial Statements (Unaudited)9ITEM 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations23ITEM 3.Quantitative and Qualitative Disclosures About Market Risk35ITEM 4.Controls and Procedures35 PART II—OTHER INFORMATION SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Report contains forward-looking statementswithin the meaning of the federal securities laws that are subject to a number ofrisks and uncertainties, many of which are beyond our control. Our forward-looking statements relate to future events or our futureperformance and include, but are not limited to, statements concerning our business strategy, future commercial revenues, marketgrowth, capital requirements, new product introductions, expansion plans and the adequacy of our funding. All statements, otherthan statements of historical fact included in this Report, are forward-looking statements. When used in this Report, the words“could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential,” “project,” or the negative Some of the risks and uncertainties that may cause our actual results, performance or achievements to differ materially from thoseexpressed or implied by forward-looking statements include the following: •the success of our plans to develop and potentially commercialize our product candidates;•the timing of the completion of preclinical studies and clinical trials;•the timing and sufficiency of patient enrollment and dosing in any future clinical trials;•the timing of the availability of data from our clinical trials;•the timing and outcome of regulatory filings and approvals;•the development of noveladeno-associated viral (AAV) vectors;•our potential future out-licenses and collaborations; •the plans of licensees of our technology; •the clinical utility and potential attributes and benefits ofDNA-directed RNA interferences (ddRNAi) and ourproduct candidates, including the potential duration of treatment effects and the potential for a “one shot” cure;•our intellectual property position and the duration of our patent portfolio;•expenses, ongoing losses, future revenue, capital needs and needs for additional financing, and our ability toaccess additional financing given market conditions and other factors;•the length of time over which we expect our cash and cash equivalents to be sufficient to execute on ourbusiness plan;•unanticipated delays;•further research and development and the results of clinical trials possibly being unsuccessful or insufficient tomeet applicable regulatory standards or warrant continued development;•the ability to enroll sufficient numbers of subjects in clinical trials;•determinations made by the U.S. Food and Drug Administration and other governmental authorities;•regulatory developments in the United States of America;•our ability to protect and enforce our patents and other intellectual property rights;•our dependence on our relationships with our collaboration partners and other third parties;•the efficacy or safety of our products and the products of our collaboration partners;•the acceptance of our products and the products of our collaboration partners in the marketplace and marketcompetition;•sales, marketing, manufacturing and distribution requirements;•greater than expected expenses, expenses relating to litigation or strategic activities;•the impact of, and our ability to remediate, the identified material weakness in our internal control overfinancial reporting; •our ability to satisfy our capital needs through increasing revenue and obtaining additional financing; and•the impact of local, regional and national and international economic conditions and events; as well as other risks detailed under the caption “Risk Factors” inour Annual Report on Form 10-K for the year ended June 30, 2025and other report